{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:13Z","timestamp":1781647213465,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose<\/jats:p>\n                  <jats:p>\n                    To simulate different dosing regimens of imatinib in third trimester pregnant women with CML that could meet plasma exposure targets for efficacy (C\n                    <jats:sub>min<\/jats:sub>\n                    \u22651000 ng\/mL) without compromising on fetal safety risk.\n                  <\/jats:p>\n                  <jats:p>Methods<\/jats:p>\n                  <jats:p>\n                    An initial physiologically-based pharmacokinetic (PBPK) model from Loer et al. was verified with routine non-pregnant PK data from a single center and then scaled to pregnancy by implementing pregnancy physiological and enzymatic changes relevant to imatinib PK. The pregnancy model was evaluated by comparing predictions with PK data observed in pregnant women receiving imatinib 400 mg once daily (QD). Simulations explored different dosing regimens that would meet C\n                    <jats:sub>min<\/jats:sub>\n                    \u22651000 ng\/mL without meaningfully higher AUC\n                    <jats:sub>0-24h<\/jats:sub>\n                    .\n                  <\/jats:p>\n                  <jats:p>Results<\/jats:p>\n                  <jats:p>\n                    Predictions for imatinib PK in the third trimester were well aligned with the observed data. Simulations indicate that 14.4% of third trimester pregnant women would achieve plasma C\n                    <jats:sub>min<\/jats:sub>\n                    \u22651000 ng\/mL at 400 mg QD, compared to 51.7% of non-pregnant female comparators receiving the same dose.\n                  <\/jats:p>\n                  <jats:p>Conclusions<\/jats:p>\n                  <jats:p>\n                    While dividing 400 mg QD into 200 mg twice daily (BID) could modestly improve PK target attainment for third trimester pregnant women (28.5%), a dose of 300 mg BID could be needed to match C\n                    <jats:sub>min<\/jats:sub>\n                    target attainment (54.2%) and AUC\n                    <jats:sub>0-24h<\/jats:sub>\n                    with expectations for a non-pregnant population receiving 400 mg QD. However, given the potential for increased fetal exposure, this approach requires careful risk-benefit assessment, and further research is warranted to establish the safest and most effective strategy.\n                  <\/jats:p>","DOI":"10.1007\/s00228-026-04049-z","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:59:12Z","timestamp":1775879952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simulation of Imatinib Pharmacokinetics in pregnant women with chronic myeloid leukemia in the third trimester"],"prefix":"10.1007","volume":"82","author":[{"given":"Paola","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne A. R.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk E. W. K.","family":"Dontje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelmer R.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs H.","family":"Oude Munnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Nieuwenhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne J.","family":"Gordijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"23","key":"4049_CR1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1408440","journal-title":"N Engl J Med"},{"issue":"25","key":"4049_CR2","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0909530","journal-title":"N Engl J Med"},{"issue":"4","key":"4049_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ctrv.2015.03.001","volume":"41","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Peccatori FA, Azim HA Jr. (2015) Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev 41(4):301\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2015.03.001","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"4049_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","volume":"62","author":"MBA van der Kleij","year":"2023","unstructured":"van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ et al (2023) Therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacokinet 62(10):1333\u20131364. https:\/\/doi.org\/10.1007\/s40262-023-01293-9","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"4049_CR5","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P et al (2008) The effects of imatinib on pregnancy outcome. Blood 111(12):5505\u20138. https:\/\/doi.org\/10.1182\/blood-2007-10-114900","journal-title":"Blood"},{"issue":"4","key":"4049_CR6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41375-024-02183-0","volume":"38","author":"E Chelysheva","year":"2024","unstructured":"Chelysheva E, Apperley J, Turkina A et al (2024) Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry. Leukemia 38(4):788\u2013795. https:\/\/doi.org\/10.1038\/s41375-024-02183-0","journal-title":"Leukemia"},{"issue":"15_suppl","key":"4049_CR7","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1200\/jco.2013.31.15_suppl.7061","volume":"31","author":"S Gundeti","year":"2013","unstructured":"Gundeti S, Goteke VKR, Maddi RN, Linga VG, Digumarti R (2013) Outcome of pregnancy in women on imatinib for CML. J Clin Oncol 31(15_suppl):7061\u20137061. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.7061","journal-title":"J Clin Oncol"},{"issue":"1","key":"4049_CR8","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.028","volume":"6","author":"E Abruzzese","year":"2014","unstructured":"Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P (2014) Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 6(1). https:\/\/doi.org\/10.4084\/mjhid.2014.028","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"7299","key":"4049_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/465689a","volume":"465","author":"F Baylis","year":"2010","unstructured":"Baylis F (2010) Pregnant women deserve better. Nature 465(7299):689\u2013690. https:\/\/doi.org\/10.1038\/465689a","journal-title":"Nature"},{"issue":"11","key":"4049_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"G Pariente","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G (2016) Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med 13(11). https:\/\/doi.org\/10.1371\/journal.pmed.1002160","journal-title":"PLoS Med"},{"issue":"2","key":"4049_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1124\/dmd.112.050245","volume":"41","author":"N Isoherranen","year":"2013","unstructured":"Isoherranen N, Thummel KE (2013) Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 41(2):256\u2013262. https:\/\/doi.org\/10.1124\/dmd.112.050245","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4049_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cpt.382","volume":"100","author":"Y Tasnif","year":"2016","unstructured":"Tasnif Y, Morado J, Hebert MF (2016) Pregnancy-related pharmacokinetic changes. Clin Pharmacol Ther 100(1):53\u201362. https:\/\/doi.org\/10.1002\/cpt.382","journal-title":"Clin Pharmacol Ther"},{"key":"4049_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00065","volume":"5","author":"MM Costantine","year":"2014","unstructured":"Costantine MM (2014) Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol 5. https:\/\/doi.org\/10.3389\/fphar.2014.00065","journal-title":"Front Pharmacol"},{"issue":"11","key":"4049_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40262-017-0539-z","volume":"56","author":"A Dallmann","year":"2017","unstructured":"Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G (2017) Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet 56(11):1303\u20131330. https:\/\/doi.org\/10.1007\/s40262-017-0539-z","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4049_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","volume":"77","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A, Groenland SL, Scherf-Clavel O et al (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77(4):441\u2013464. https:\/\/doi.org\/10.1007\/s00228-020-03014-8","journal-title":"Eur J Clin Pharmacol"},{"key":"4049_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00177","volume":"11","author":"T Buclin","year":"2020","unstructured":"Buclin T, Thoma Y, Widmer N, Csajka C (2020) The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol 11","journal-title":"Front Pharmacol"},{"issue":"10","key":"4049_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/psp4.12551","volume":"9","author":"S Cole","year":"2020","unstructured":"Cole S, Coppola P, Kerwash E, Nooney J, Lam SP (2020) Pharmacokinetic Characterization to Enable Medicine Use in Pregnancy, the Potential Role of Physiologically-Based Pharmacokinetic Modeling: A Regulatory Perspective. CPT Pharmacometrics Syst Pharmacol 9(10):547\u2013549. https:\/\/doi.org\/10.1002\/psp4.12551","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"4049_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/psp4.12274","volume":"7","author":"AB Ke","year":"2018","unstructured":"Ke AB, Greupink R, Abduljalil K (2018) Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations. CPT Pharmacometrics Syst Pharmacol 7(2):103\u2013110. https:\/\/doi.org\/10.1002\/psp4.12274","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"4049_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T et al (2016) Applied Concepts in PBPK Modeling: How to Build a PBPK\/PD Model. CPT Pharmacometrics Syst Pharmacol 5(10):516\u2013531. https:\/\/doi.org\/10.1002\/psp4.12134","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"4049_CR20","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/cpt.1084","volume":"104","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Pfister M, van den Anker J, Eissing T (2018) Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models. Clin Pharmacol Ther 104(6):1110\u20131124. https:\/\/doi.org\/10.1002\/cpt.1084","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4049_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jcph.2379","volume":"64","author":"XI Liu","year":"2024","unstructured":"Liu XI, Leong R, Burckart GJ, Dallmann A (2024) Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug-Drug Interactions, Pediatric Patients, and Pregnancy and Lactation. J Clin Pharmacol 64(3):323\u2013333. https:\/\/doi.org\/10.1002\/jcph.2379","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4049_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/psp4.12300","volume":"7","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Solodenko J, Ince I, Eissing T (2018) Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women. CPT Pharmacometrics Syst Pharmacol 7(7):419\u2013431. https:\/\/doi.org\/10.1002\/psp4.12300","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"4049_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.7","volume":"2","author":"E Manolis","year":"2013","unstructured":"Manolis E, Rohou S, Hemmings R, Salmonson T, Karlsson M, Milligan PA (2013) The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA\/EMA Modeling and Simulation Workshop. CPT Pharmacometrics Syst Pharmacol 2(2). https:\/\/doi.org\/10.1038\/psp.2013.7","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"Suppl 1","key":"4049_CR24","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1002\/jcph.2224","volume":"63","author":"R Leong","year":"2023","unstructured":"Leong R, Grimstein M, DeMaria P, Norsworthy KJ, Fletcher EP, Shord S (2023) Landscape and Regulatory Perspective on Oncology Drugs in Pregnancy. J Clin Pharmacol 63(Suppl 1):S170-s175. https:\/\/doi.org\/10.1002\/jcph.2224","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4049_CR25","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640\u20132653. https:\/\/doi.org\/10.1182\/blood-2004-08-3097","journal-title":"Blood"},{"issue":"9","key":"4049_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894. https:\/\/doi.org\/10.2165\/00003088-200544090-00001","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4049_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/jco.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B, Hayes M, Resta D et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22(5):935\u201342. https:\/\/doi.org\/10.1200\/jco.2004.03.050","journal-title":"J Clin Oncol"},{"key":"4049_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13127","author":"HLH Loer","year":"2024","unstructured":"Loer HLH, Kovar C, R\u00fcdesheim S et al (2024) Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. CPT: Pharmacometrics & Systems Pharmacology. https:\/\/doi.org\/10.1002\/psp4.13127","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"4049_CR29","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3389\/fphar.2019.01672","volume":"10","author":"J Adiwidjaja","year":"2019","unstructured":"Adiwidjaja J, Boddy AV, McLachlan AJ (2019) Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in paediatrics. Front Pharmacol 10:1672. https:\/\/doi.org\/10.3389\/fphar.2019.01672","journal-title":"Front Pharmacol"},{"issue":"10","key":"4049_CR30","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1124\/dmd.105.004283","volume":"33","author":"HP Gschwind","year":"2005","unstructured":"Gschwind HP, Pfaar U, Waldmeier F et al (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33(10):1503\u201312. https:\/\/doi.org\/10.1124\/dmd.105.004283","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"4049_CR31","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G, Koller D, Zubiaur P, Abad-Santos F (2019) Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. Clin Ther 41(12):2558-2570e7. https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.009","journal-title":"Clin Ther"},{"issue":"6","key":"4049_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40262-017-0594-5","volume":"57","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G (2018) A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Clin Pharmacokinet 57(6):749\u2013768. https:\/\/doi.org\/10.1007\/s40262-017-0594-5","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"4049_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.2008.1","volume":"84","author":"MF Hebert","year":"2008","unstructured":"Hebert MF, Easterling TR, Kirby B et al (2008) Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 84(2):248\u201353. https:\/\/doi.org\/10.1038\/clpt.2008.1","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4049_CR34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/aog.0000000000001972","volume":"129","author":"RM Burwick","year":"2017","unstructured":"Burwick RM, Kuo K, Brewer D, Druker BJ (2017) Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. Obstet Gynecol 129(5):831\u2013834. https:\/\/doi.org\/10.1097\/aog.0000000000001972","journal-title":"Obstet Gynecol"},{"issue":"2","key":"4049_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","volume":"280","author":"R Ali","year":"2009","unstructured":"Ali R, Ozkalemkas F, Kimya Y et al (2009) Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 280(2):169\u201375. https:\/\/doi.org\/10.1007\/s00404-008-0861-7","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"4049_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.jp.7211665","volume":"27","author":"MA Russell","year":"2007","unstructured":"Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ (2007) Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27(4):241\u2013243. https:\/\/doi.org\/10.1038\/sj.jp.7211665","journal-title":"J Perinatol"},{"issue":"8","key":"4049_CR37","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022\u20134028. https:\/\/doi.org\/10.1182\/blood-2007-10-116475","journal-title":"Blood"},{"key":"4049_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081676","author":"H Johnson-Ansah","year":"2022","unstructured":"Johnson-Ansah H, Maneglier B, Huguet F et al (2022) Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14081676","journal-title":"Pharmaceutics"},{"issue":"22","key":"4049_CR39","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/cncr.34478","volume":"128","author":"F Cheng","year":"2022","unstructured":"Cheng F, Zeng F, Li Q et al (2022) Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia. Cancer 128(22):3951\u20133958. https:\/\/doi.org\/10.1002\/cncr.34478","journal-title":"Cancer"},{"key":"4049_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041081","author":"S Goutelle","year":"2023","unstructured":"Goutelle S, Guidi M, Gotta V, Csajka C, Buclin T, Widmer N (2023) From personalized to precision medicine in oncology: a model-based dosing approach to optimize achievement of imatinib target exposure. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15041081","journal-title":"Pharmaceutics"},{"issue":"8","key":"4049_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","volume":"9","author":"E Abruzzese","year":"2016","unstructured":"Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M (2016) Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol 9(8):781\u201391. https:\/\/doi.org\/10.1080\/17474086.2016.1205479","journal-title":"Expert Rev Hematol"},{"issue":"14","key":"4049_CR42","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/jco.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381\u20138. https:\/\/doi.org\/10.1200\/jco.2009.26.3087","journal-title":"J Clin Oncol"},{"issue":"7","key":"4049_CR43","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40262-020-00861-7","volume":"59","author":"P Mian","year":"2020","unstructured":"Mian P, Allegaert K, Conings S et al (2020) Integration of placental transfer in a fetal-maternal physiologically based pharmacokinetic model to characterize acetaminophen exposure and metabolic clearance in the fetus. Clin Pharmacokinet 59(7):911\u2013925. https:\/\/doi.org\/10.1007\/s40262-020-00861-7","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04049-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04049-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04049-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:48:39Z","timestamp":1781646519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04049-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4049"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04049-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"PMa is a full-time employee of Ionis and may hold Ionis stock or options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors give permission to reproduce materials from other sources.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce materials from other sources"}}],"article-number":"121"}}